A Phase 4 interventional study of Suzetrigine and Placebo in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.
Among the 21 studies testing suzetrigine in Pain, this one is the 9th largest by enrollment, is one of 6 that started in 2026, is one of 3 in phase 4, and was the 18th registered.
10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.
Browse Pain studies →4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Hospital for Special Surgery, New York · Sites in United States
Ages 18–80 · Healthy volunteers
Stanford University · Sites in United States
Ages 18+
Jacob Lensing · Sites in United States
Ages 18–45
By country, each count listing its studies:
suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →
Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 6 started in 2026.
This study's enrollment of 66 is close to the median of 66 across 8,502 interventional studies indexed under Pain.
Median enrollment 50 across the 21 interventional studies. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 6 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
26 studies in Pain by Vertex Pharmaceuticals Incorporated: none open now, none under way, none of them phase 3. Of 26 finished, 1 (4%) have results posted.
Among the 26 studies in Pain by Vertex Pharmaceuticals Incorporated, this one is the 7th largest by enrollment, is one of 3 that started in 2026, is the only one in phase 4, and was the 25th registered.
Vertex Pharmaceuticals Incorporated’s Pain studies by the year they started, since 2022.
2 of the studies testing suzetrigine in Pain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07226700Phase 3Hospital for Special Surgery, New YorkSuzetrigine in Total Hip Arthroplasty | 2027-11-01 |
| NCT07821931Stanford UniversitySuzetrigine in Tonsillectomy for Opioid-sparing Pain Management | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies testing suzetrigine in Pain, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 26 in Pain:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).
Key Inclusion Criteria:
Key Exclusion Criteria:
- History of previous TKA surgery on incident side
Other protocol defined Inclusion/Exclusion criteria will apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SUZ for 14 days.
Drug: Suzetrigine
Participants will receive placebo matched to SUZ for 14 days
Drug: Placebo
Tablets for oral administration.
Also known as: VX-548, JOURNAVX
Placebo matched to SUZ for oral administration
Total Opioid Usage
Time frame: 24 hours to 168 hours after the first dose of study drug
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Oct 2026, 5 months.
Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 5 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2027 → Oct 2026 and completion Jan 2027 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →